

Index

Note: Page numbers of article titles are in **boldface** type.

A

- Acanthamoeba*, 484–485
- Achromobacter*, MALDI-TOF mass spectrometry for, 572
- Actinomyces*, MALDI-TOF mass spectrometry for, 574
- Adenoviruses, 448–449, 451, 453, 528, 534–536
- Adrenomedullin, in sepsis, 417, 420
- Aeromonas*, 528, 535
- Affirm VPIII assay, 473, 489
- African trypanosomiasis, 467–468
- Aichi virus, 534
- Alere Determine TB-LAM Ag lateral flow test, 559
- Algorithms, clustering, in MALDI-TOF mass spectrometry, 620–622
- Amebiasis, 485–488
- American trypanosomiasis (Chagas disease), 476–477
- Amoeba, free-living, 470, 484–485
- Amplicor *Mycobacterium tuberculosis* test, 554
- Amplified *Mycobacterium tuberculosis* Direct Test, 554
- AmpliVue *C difficile* test, 530–531, 534
- Anaerobic bacteria
 - in blood cultures, 652
 - MALDI-TOF mass spectrometry for, 574
- Ancylostoma*, 487–488
- Antibiotic Resistance Genes Database, 644
- Antigen85, in tuberculosis, 561
- Antigen-detection tests, for respiratory viruses, 440
- Antimicrobial resistance
 - in blood culture pathogens, 665–667
 - MALDI-TOF mass spectrometry for, 602, 623
- Antimicrobial susceptibility testing, 415, 695
- Aptamers, in tuberculosis, 560–561
- Aptima *Trichomonas vaginalis* assay, 473, 489
- Arabinitol, in fungal infections, 540–541
- Ascaris lumbricoides*, 486–488
- Aspergillosis
 - biomarkers in, 506–511
 - molecular diagnosis of, 512–519
- Aspergillus*, MALDI-TOF mass spectrometry for, 575–597, 616
- Aspergillus* Real-Time PCR Panel, 512–514, 516
- Astroviruses, 528, 534–535
- Auroeobasidium/Hormonema*, MALDI-TOF mass spectrometry for, 576
- Automation, **567–588**
 - business case for, 584–587

Automation (*continued*)

- digital imaging in, 579–582
- history of, 706–707
- importance of, 567–569
- liquid microbiology and, 569–571
- of blood culture microorganism detection, 651–652, 664–665
- of polymicrobial blood culture identification, 614–615
- preanalytical, 571–578
- total laboratory, 582–584

B

- Babesiosis, 446, 475–476
- BACcel, for blood cultures, 671, 673
- Bacillus*, MALDI-TOF mass spectrometry for, 574
- BacT FX system, for blood cultures, 652
- BacT/ALERT system, for blood cultures, 652, 664–665
- BACTEC Lytic/10 bottles, for blood cultures, 665
- BACTEC Plus, for blood cultures, 665
- BACTEC/ALERT, for blood cultures, 671–672
- Bacteremia, sepsis in. *See* Sepsis.
- Bacteria, MALDI-TOF mass spectrometry for, 572–595
- Bacterial strain typing. *See* Strain typing.
- Bacteriophages, in Keypath MRSA/MSSA Blood Culture Test, 668
- Bacteroides fragilis*, MALDI-TOF mass spectrometry for, 603, 623
- Balmuthia mandrillaris*, 484–485
- BD Max System, 655–656
- BDG Fungitell assay, 509–510
- Beta-lactamase, *Mycobacterium tuberculosis*, 561
- Bile solubility test, for blood cultures, 664, 673
- Binary typing, 633, 643–645
- BinaxNOW *Staphylococcus aureus* assay, for blood cultures, 668, 673
- BioFire assays, for respiratory viruses, 451–453
- Bioinformatics, 645
- Biomarkers
 - for fungal infections, 506–511, 519
 - for gastroenteritis, 543
 - for *Mycobacterium tuberculosis*, 558–562
 - for sepsis, 415–422
- bioMérieux VITEX 2ID, 671–672, 709
- bioMérieux VITEX MS
 - description of, 590–592, 612
 - for bacteria identification, 592–595
 - for blood cultures, 671–672
 - for fungi identification, 595–597
- Biosensors, for gastroenteritis, 541–543
- Blastocystis hominis*, 487
- Blastomyces dermatitidis*, 509
- Blood cultures
 - contamination of, 652
 - microorganism detection in, **651–684**

- Candida*, 665–666, 669–671
 - Enterococcus*, 656–658, 669–670
 - Escherichia coli*, 658, 669–670
 - Exosporohilum rostratum*, 519
 - false-negative results of, 652
 - fungi, 505–506, 615–617, 657–661
 - Gram-negative bacteria, 657–661
 - Gram-positive bacteria, 615, 657–661
 - history of, 651–653
 - in sepsis, 414–415, 422–423, 426, 428
 - Klebsiella*, 669–670
 - Listeria*, 656
 - MALDI-TOF mass spectrometry for, 601, 613–617
 - nanotechnology for, 656–657
 - nucleic acid amplification tests for, 653–662
 - polymicrobial, 614–615
 - Pseudomonas aeruginosa*, 669–670
 - pyrosequencing, 659
 - rapid, 707
 - specimen processing for, 613–614
 - Staphylococcus*, 653–656
 - Staphylococcus aureus*, 665, 668, 674
 - Streptococcus*, 659, 672
 - Streptococcus pneumoniae*, 664, 671
 - subculture of, 652
- Bloodstream infections. *See also* Blood cultures.
- MALDI-TOF mass spectrometry for, 613–617
 - sepsis in. *See* Sepsis.
- Bocaviruses, 535
- Bordetella pertussis*, 540
- Bovine herpes virus, 544
- Bovine respiratory syncytial virus, 544
- Bovine viral diarrhea virus, 541
- Breath, tuberculosis biomarkers in, 559–560
- Bronchoalveolar fluid analysis, in fungal infections, 506–508
- Brugia malayi*, 468, 479–480
- Bruker MALDI BioTyper, 612
- description of, 590–592
 - for bacteria identification, 592–595
 - for blood cultures, 671–672
 - for fungi identification, 595–597
- Burkholderia*
- MALDI-TOF mass spectrometry for, 574
 - strain typing of, 642

C

- CALC-1 gene, in sepsis, 418
- Campylobacter*, 536, 539
- Campylobacter coli*, 535
- Campylobacter jejuni*, 528, 534–535, 541

Candida

- biomarkers in, 506–511
 - in blood cultures, 665–667, 669–673
 - MALDI-TOF mass spectrometry for, 575–597, 614–617
 - molecular diagnosis of, 511–528
- Candida albicans* germ tube antibody assay, 509
- Candida* Real-Time PCR Panel, 512–513, 515–516
- Capillary gel electrophoresis, for strain typing, 636, 638
- Capillary Sanger sequencing, for strain typing, 639
- Capillary sequence platforms, for strain typing, 636, 638
- Carbapenemases, MALDI-TOF mass spectrometry for, 602
- Card agglutination test, for African trypanosomiasis, 478
- Cell culture, for respiratory viruses, 440
- Cell lysis, for blood cultures, 613–614
- Cell-analysis, real-time, for gastroenteritis, 545–546
- Centrifugation, of urine specimens, for MALDI-TOF mass spectrometry, 617–618
- Cepheid assays, for respiratory viruses, 443–445
- Cestodes, 487–488
- cfiA* gene, *Bacteroides fragilis*, 623
- Chagas disease, 466, 476–477
- Chemical protein extraction, for blood cultures, 613–614
- Chemiluminescence assay, for sepsis, 417, 421
- Chemiluminescence sandwich immunoassay, for procalcitonin, 418
- Chlamydomphila*, strain typing of, 639
- Cholera toxin, 542
- CHROMagar *Candida*, for blood cultures, 665–667
- CHROMagar MRSA, for blood cultures, 667
- Chromogenic agar, for blood cultures, 665–667, 673
- Ciphergen Protein-Chip System, for African trypanosomiasis, 479
- ClinProTools, 619
- Clonality, MALDI-TOF mass spectrometry for, 622
- Clonorchis sinensis*, 488
- Clostridium*, strain typing of, 635
- Clostridium difficile*, 528, 530–534–536, 545–546, 721
- MALDI-TOF mass spectrometry for, 622
 - typing of, 632, 636–637
- Clostridium perfringens*, 535, 546
- Clustered, regularly interspersed short palindromic repeats (CRISPRs), for strain typing, 632
- Clustering algorithms, in MALDI-TOF mass spectrometry, 620–622
- Coinfections, of respiratory viruses, 455
- CompassXport tool, 618–619
- Compensatory antiinflammatory response syndrome, 415
- Comprehensive Antibiotic Resistance Database, 644
- Computers, in sequencing, 694
- Conductometric biosensors, for gastroenteritis, 542
- Confusion matrix, in MALDI-TOF mass spectrometry, 620–621
- Consensus multilocus sequence typing, 632, 639–640
- Coronaviruses, molecular diagnosis of, 451, 454
- Corynebacterium*, MALDI-TOF mass spectrometry for, 574

- C-reactive protein
 - in gastroenteritis, 543
 - in sepsis, 416–418
- CRISPRs (clustered, regularly interspersed short palindromic repeats), for strain typing, 632
- Crohn disease, 543
- Cronobacter*, strain typing of, 635
- Cryptococcus*, MALDI-TOF mass spectrometry for, 575–576
- Cryptosporidiosis, 471, 485–488, 536, 544
- Culture-independent diagnostic testing, 645–646
- Cultures. *See also* Blood cultures.
 - for free-living amoeba, 485
 - for fungal infections, 505–506
 - for gastroenteritis, 528–529
 - for leishmaniasis, 481
- α -Cyano-4-hydroxycinnamic acid, in MALDI-TOF mass spectrometry, 612, 623
- Cytokines
 - in gastroenteritis, 543–544
 - in sepsis, 417, 421

D

- Data storage, in sequencing, 691
- Databases, for sequencing, 692
- Decision support, 723
- Definitions Biomarkers Working Group, 506
- Determine TB-LAM Ag lateral flow test, 559
- Diafiltration, of urine specimens, for MALDI-TOF mass spectrometry, 617–618
- Diarrhea. *See also* Gastroenteritis.
 - in parasitic disease, 470–472, 485–488
- Dientamoeba fragilis*, 471, 487
- Differential centrifugation, for blood cultures, 613–614
- Digital imaging, 579–582
- Direct Amplification Disk, 446
- Direct bile solubility test, for blood cultures, 664, 673
- Direct tube coagulation test, for blood culture, 662
- Disk diffusion susceptibility test, 708
- Diversity, in sequencing, 690
- DNase test, thermostable, for blood cultures, 664, 673

E

- Electrical impedance detection methods, for gastroenteritis, 545
- Electrochemical impedimetric immunosensors, for gastroenteritis, 541–542
- Electron microscopy, for gastroenteritis, 528–529
- Electronic medical records, 722–723
- Electrophoresis, pulsed field gel, for strain typing, 631–632, 634–636
- Electrospray ionization mass spectrometry, 659–670
 - for babesiosis, 476
- emm* gene, for strain typing, 632, 639
- Encephalitozoon*, 489–490

- Endotoxin, in sepsis, 417, 421–422
- Endotoxin activity assay, for sepsis, 417, 421
- Entamoeba gingivalis*, 486
- Entamoeba histolytica*, 536
- Entamoeba histolytica/dispar*, 470, 485–488
- Enterobacteriaceae*, MALDI-TOF mass spectrometry for, 601
- Enterococcus*
 - in blood cultures, 656, 669–670
 - strain typing of, 635
 - vancomycin resistance and susceptibility in, MALDI-TOF mass spectrometry for, 601, 603, 622
- Enterocytozoon*, 489–490
- Enteroviruses, 452, 454, 534
- Enzyme immunoassay, for gastroenteritis, 528
- Enzyme-linked immunosorbent assay
 - for filariasis, 480
 - for gastroenteritis, 543
 - for tuberculosis, 561
 - Hyplex BloodScreen assay with, 661–662
- Epidemiology, MALDI-TOF mass spectrometry for, 622
- Epstein-Barr virus, PCR for, 718–719
- Escherichia*, strain typing of, 635, 638
- Escherichia coli*, 528, 534–536, 541–542
 - antibiotic resistance in, 602
 - in blood cultures, 658, 669–670
 - misidentification of, 612
 - strain typing of, 643
- eSensor Respiratory Viral Panel, 449
- ESwab, 570
- European *Aspergillus* PCR Initiative, 518
- European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, 508
- Exosporohilum rostratum*, 519

F

- Filariasis, 467–468
- FilmArray Blood Culture Identification panel, 657–659, 662–663
- FilmArray GI assay, 487
- FilmArray Respiratory Panel, 451–453
- Filter paper, of urine specimens, for MALDI-TOF mass spectrometry, 617–618
- Fluconazole resistance, in blood cultures, 666
- Flukes, 487–488
- Fluorescence microscopy. *See* PNA FISH (peptide nucleic acid fluorescent in situ hybridization assay).
- Fluorescent resonance energy transfer (FRET), for malaria, 463
- Focus Diagnostic assays, for respiratory viruses, 445–446
- Fontana Masson strain, for fungi, 519
- Formalin-fixed paraffin-embedded tissues, fungi in, 519
- Foundation for Innovative New Diagnostics, 479
- Free-living amoebae, 484–485

Fructobacillus, MALDI-TOF mass spectrometry for, 622
Fungal infections, **505–525**
 biomarkers for, 506–511, 519
 MALDI-TOF mass spectrometry for, 615–617
 molecular diagnosis of, 511–518
Fungitell assay, 509–510
Fusarium, MALDI-TOF mass spectrometry for, 597, 616

G

Galactomannan, in fungal infections, 506–509
Ganglioside-sensitized liposomes, for gastroenteritis, 542
Gastroenteritis, **528–552**
 biosensors for, 541–545
 genomic assays for, 529–540
 historical detection methods for, 527–529
 multiplex PCR for, 534–537, 721
 proteomics for, 529, 541–546
 real-time cell analysis systems for, 545–546
Gel-based separation, for blood cultures, 613–614
GeneOhm Cdiff Assay, 530–531
GeneOhm StaphSR assay, 655–656, 662–663
GeneXpert Flu Assay, 443–444
GeneXpert MRSA/SA blood culture assay, 653–664, 672–674, 709
GeneXpert Xpert MTV/RIF test, 556–558
GenMark assays, for respiratory viruses, 448–449
Genome analysis, for gastroenteritis, 539
Genomic assays, for gastroenteritis, 529–540
Genotype MTDR test, 555–556
GenoType Mycobacteria Direct test, 554
Giardiasis, 471, 485–488, 536
1,3- β -D-Glucan, in fungal infections, 509–540
Glutamate dehydrogenase antigen test, for gastroenteritis, 528
Gold nanotechnology, for blood cultures, 656–657
G-protein-coupled receptors, for gastroenteritis, 545
Gram-negative organisms, MALDI-TOF mass spectrometry for, 602, 715–717
Gram-positive bacteria, MALDI-TOF mass spectrometry for, 615

H

HACEK organisms, MALDI-TOF mass spectrometry for, 597
Helicase method, for *Staphylococcus* detection, 654
Helicobacter pylori, 544
HeliScope System, for gastroenteritis, 539–540
Helminths, intestinal, 470–472, 485–488
High-resolution fragment analysis, for strain typing, 632, 636–638
Histoplasma capsulatum, in blood cultures, 652
Hologic assays, for respiratory viruses, 442–443
Human metapneumovirus, molecular diagnosis of, 442–443, 448, 451
Hyplex BloodScreen assay, 661–663
 for sepsis, 423, 427

I

- Illumigene *C difficile* Assay, 530–532
- Immunochromatography
 - for blood cultures, 668
 - for filariasis, 480
- Immunocytotoxicity assay, in gastroenteritis, 545
- Immunoenzymatic microplate sandwich assay, for fungal infections, 506
- Immunoglobulin, salivary, in gastroenteritis, 544
- Immunoluminometric procalcitonin assay, for sepsis, 419
- Immunoparalysis, in sepsis, 415
- Immunosensors, for gastroenteritis, 541–543
- Incidental findings, in sequencing, 694–695
- Incubators, digital imaging in, 579–582
- Infectious Diseases Society of America, fungal infection guidelines of, 508
- Influenza virus, molecular diagnosis of, 443–453
- INNO-LiPA TB test, 555
- Innova plating instrument, 571–572, 574–575
- InocuLAB, 573
- InoqulA plating instrument, 571–572, 575–576
- Interferons
 - in gastroenteritis, 543–544
 - in *Mycobacterium tuberculosis*, 559, 561
- Interleukins
 - in gastroenteritis, 543–544
 - in sepsis, 417, 421
- Intestinal parasites, 470–472, 485–488
- Ion Proton System, for gastroenteritis, 540
- IQuum assays, for respiratory viruses, 445
- Isoplater, 571, 573

K

- Keypath MRSA/MSSA Blood Culture Test, 668
- Klebsiella*, in blood cultures, 669–670
- K-mer based approaches, to strain typing, 632, 642

L

- Label-free detection methods, for gastroenteritis, 545
- Lactococcus*, MALDI-TOF mass spectrometry for, 622
- LCx, *M tuberculosis* test, 554
- LDMS, for malaria, 465
- Leishmaniasis, 469, 481–482
- Leishmanin skin test, 481–482
- Leuconostoc*, MALDI-TOF mass spectrometry for, 622
- LIASON BRAHMS PCT-immunoluminometric assay, for procalcitonin, 419
- Liat Influenza A/B assay, 445
- Line probe assays, for *Mycobacterium tuberculosis*, 558
- Lipoarabinomannan, in tuberculosis, 559
- Lipopolysaccharide-binding protein, in sepsis, 417, 419–420
- Liquid microbiology, 569–571

Listeria

- in blood cultures, 656
- MALDI-TOF mass spectrometry for, 574, 603
- strain typing of, 603, 639

Loa loa, 468, 479–480

Loop-mediated isothermal amplification

- for African trypanosomiasis, 467–468, 478–479
- for leishmaniasis, 469
- for malaria, 465, 474–475
- for *Mycobacterium tuberculosis*, 557–558
- for toxoplasmosis, 470, 484

Luminex assays

- for intestinal parasites, 486
- for respiratory viruses, 449–451

Luminex Multiplex PCR xMAP assay, for fungal infections, 512–513

Luminex xMAP technology, for gastroenteritis, 535

Lymphatic filariasis, 467–468

Lysis centrifugation, for blood cultures, 652

M

Malaria, 462–465, 474–475, 540

MALDI Sepsityper kit, 601, 671–673

MALDIquant, 620

MALDI-TOF mass spectrometry, **589–609**, 709–717

- clinical utility of, 710–717
- commercial systems for, 590–592
- costs of, 598, 710
- dangers of, 711
- description of, 710
- disadvantages of, 711
- economics of, 710
- emerging uses of, **611–628**
 - bloodstream infections, 613–617
 - classification, 619–620
 - clustering algorithms, 620–622
 - limitations of, 612–613
 - postanalytical, 618–622
 - spectra refinements, 618–619
 - urinary tract infections, 617–618
- for antimicrobial resistance detection, 602, 623
- for blood cultures, 673, 715–717
- for clonality studies, 622
- for epidemiologic information, 622
- for microbial identification
 - advantages of, 597–598
 - bacteria, 592–595
 - direct, 601–602
 - disadvantages of, 599–600
 - fungi, 517, 595–597
 - Gram-negative, 715–717

MALDI-TOF (*continued*)

- principles of, 590–592
 - Streptococcus*, 716
 - for strain typing, 602–603, 622
 - future applications of, 600–603
 - history of, 589–599
 - implementation of, 714
 - patient benefits of, 714
 - unusual organisms found in, 712–714
 - work flow with, 710–711
- Mannan, in fungal infections, 540–541
- Mansonella*, 479–480
- Mass spectrometry
- for babesiosis, 476
 - for malaria, 475
 - matrix-assisted laser desorption ionization-time-of-flight. *See* MALDI-TOF mass spectrometry.
 - PCR with, for blood cultures, 663
- MassSpecWavelet, 620
- MATLAB, 620
- Matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF).
- See* MALDI-TOF mass spectrometry.
- MEDIC (Multicenter Endotoxin Detection in Critical Illness) trial, 417, 421
- Medical education, for sequencing, 696
- Medical laboratory technologists, 569
- Meningitis outbreak of 2012, investigation of, 519
- Meningococcus Genome Informatics Platform, 639
- Metabolomics, for *Mycobacterium tuberculosis*, 561
- Metagenomics, 689–690
- Methicillin resistance, in *Staphylococcus aureus*. *See* MRSA (methicillin-resistant *Staphylococcus aureus*).
- Microscopy
- for African trypanosomiasis, 478
 - for filariasis, 480
 - for free-living amoebae, 485
 - for gastroenteritis, 528
 - for intestinal helminths, 487–488
 - for leishmaniasis, 481
 - for microsporidia, 489
 - for trichomoniasis, 488–489
- Microsporidiosis, 473, 489–490
- Minimum Information for Publication of Quantitative Real-Time PCR Experiments guidelines, 511
- Mixed inflammatory response syndrome, 415
- MLST (multilocus sequence typing), 632, 639–640
- Molecular diagnosis, 717–722. *See also individual methods and infections.*
- for fungal infections, 511–518
 - for *Mycobacterium tuberculosis*, 554–558
 - for respiratory viruses, 441–455
 - for sepsis, 422–429
 - product selection for, 717–718

- quantitative testing in, 718
- Molecular phylogeny, 687–689
- MoYsis Basic kit, 601
- Moraxella*, MALDI-TOF mass spectrometry for, 621
- MRSA (methicillin-resistant *Staphylococcus aureus*)
 - antibiotic resistance in, MALDI-TOF mass spectrometry for, 602
 - in blood cultures, 653–657, 663, 665–668, 674
 - in sepsis, 422, 424–425
 - MALDI-TOF mass spectrometry for, 602–603, 622
 - strain typing of, 632, 638–640
- MRSA ID, 667
- Mucorales*, MALDI-TOF mass spectrometry for, 597
- Multicenter Endotoxin Detection in Critical Illness (MEDIC) trial, 417, 421
- Multilocus sequence typing, 632, 639–640
- Multiple locus VNTR analysis, for strain typing, 636, 638
- Multiplex PCR, 719
 - for African trypanosomiasis, 478–479
 - for babesiosis, 476
 - for blood cultures, 658
 - for free-living amoebae, 485
 - for gastroenteritis, 534–538, 721
 - for intestinal parasites, 486–487
- Multiplex protein/antigen liquid arrays, for gastroenteritis, 543–544
- Multiplex xTAG Fungal ASR Luminex assay, 512, 514
- MycAssay *Aspergillus*, 512, 515–516
- Mycobacterium*
 - in blood cultures, 652
 - MALDI-TOF mass spectrometry for, 574
 - strain typing of, 635, 643
- Mycobacterium tuberculosis*, **553–566**
 - biomarkers for, 558–562
 - MALDI-TOF mass spectrometry for, 574
 - molecular diagnosis of, 554–558
 - multidrug-resistant, 555–556, 568

N

- NAATs. *See* Nucleic acid amplification tests; *specific tests*.
- Naegleria fowleri*, 484–485
- Nanosphere assays, for respiratory viruses, 446–448
- Nanotechnology, for blood cultures, 656–657
- National Institute of Allergy and Infectious Diseases Mycoses Study Group, 508–511
- Necator americanus*, 487–488
- Neisseria*, strain typing of, 639, 642
- Nematodes, 487–488
- NeutrAvidin, for gastroenteritis, 542
- Next-generation sequencing-based microbiota determination, for gastroenteritis, 538–540
- Nitrocellulose nanofibrous membrane, for gastroenteritis, 541
- Nitrous oxide, in gastroenteritis, 543–544
- Nocardia*, MALDI-TOF mass spectrometry for, 574
- Noninstrumented nucleic acid platform, for malaria, 465, 475

Norovirus, 528, 534–536

Nosema, 489–490

Nucleic acid amplification tests

for African trypanosomiasis, 478–479

for babesiosis, 475–476

for blood cultures, 653–662

for intestinal helminths, 487–488

for malaria, 463–465, 474–475

for microsporidia, 489–490

for *Mycobacterium tuberculosis*, 554–558

for respiratory viruses, 441–455

for sepsis, 422–429

Nucleic acid lateral flow immunoassay (NALFIA), for malaria, 475

Nucleic acid sequencing. See Sequencing.

Nucleic acid-based sequenced -based amplification (NASBA)

for African trypanosomiasis, 479

for malaria, 474–475

O

Oligochromatography, for African trypanosomiasis, 467, 479

Oligonucleotides, in tuberculosis, 560–561

Onchocerca volvulus, 479–480

Optoelectric immunosensors, for gastroenteritis, 542–543

P

Paecilomyces, 513

Paraffin-embedded tissues, fungi in, 519

Paraflagellar rod protein A, in African trypanosomiasis, 478–479

Parainfluenza viruses, 448, 451, 453–454, 544

Parasitic diseases, **461–503**

blood, 462–468, 474–480

intestinal, 470–472, 485–488

tissue, 469–470, 481–485

urogenital, 483, 488–489

versus microsporidia, 489–490

Parechoviruses, 534

PCR. See Polymerase chain reaction.

PCR-ribotyping, for strain typing, 632, 636–637

Penicillium, MALDI-TOF mass spectrometry for, 616

Pentraxin 3, in sepsis, 417, 421

Peptide nucleic acid fluorescent in situ hybridization assay. See PNA FISH (peptide nucleic acid fluorescent in situ hybridization assay).

Phenotypic methods, for blood cultures, 662, 664–672

Phoenix automated identification system, for blood cultures, 664–665

Pichia, MALDI-TOF mass spectrometry for, 576

Plasmodium, 540

Platelia kit, for fungal infections, 507–508

Platelia mannan antigen test, 510

- Plating techniques, automation for, 569–582
- PLEX-ID BAC Spectrum assay, 424, 428, 476
- PLEX-ID Broad Fungal Assay, 512, 515–516
- PNA FISH (peptide nucleic acid fluorescent in situ hybridization assay), 709
 - for African trypanosomiasis, 467
 - for blood cultures, 668–673
 - for fungal infections, 514, 518
- Pneumocystis*, biomarkers in, 510
- Polymerase chain reaction
 - electrospray ionization mass spectrometry with, 659–670
 - for African trypanosomiasis, 467–468, 478–479
 - for babesiosis, 466, 475–476
 - for blood culture microorganisms, 653–662
 - for Chagas disease, 466, 476–477
 - for cryptosporidiosis, 471
 - for *Dientamoeba fragilis*, 471, 487
 - for *Entamoeba histolytica/dispar*, 470
 - for Epstein-Barr virus, 718–719
 - for filariasis, 468, 480
 - for free-living amoebae, 470, 485
 - for fungal infections, 511–518
 - for gastroenteritis, 534–538
 - for giardiasis, 471
 - for intestinal parasites, 473–474, 486–488
 - for leishmaniasis, 469, 481–482
 - for malaria, 465–466, 474–475
 - for microsporidiosis, 474
 - for *Mycobacterium tuberculosis*, 554–555
 - for respiratory viruses, 441–455
 - for schistosomiasis, 473
 - for sepsis, 422–429
 - for toxoplasmosis, 470, 482–484
- Polymicrobial blood cultures, 614–615, 672
- Portrait Toxigenic *C difficile* Assay, 530–531, 533
- Postanalytical approach, MALDI-TOF mass spectrometry for, 618–622
- Post-transplant lymphoproliferative disease, 718–719
- Preamalytical automation, 571–578
- PREVI Isola plating instrument, 571–572, 578
- Principal-component analysis, in MALDI-TOF mass spectrometry, 620
- Privacy issues, in sequencing, 694
- Pro-adrenomedullin, in sepsis, 417, 420
- ProbeTec Direct Test, for *Mycobacterium tuberculosis*, 554
- Procalcitonin, in sepsis, 417–419
- Prodesse kits, for respiratory viruses, 442–443
- ProGastro CD assay, 530–532
- Proteomics
 - for gastroenteritis, 529, 541–546
 - for *Mycobacterium tuberculosis*, 561
- Provasopressin, in sepsis, 417, 420
- Prove-it Sepsis assay, 423, 426–427, 661, 663

Pseudomonas aeruginosa

- in blood cultures, 669–670

- MALDI-TOF mass spectrometry for, 574

Pulsed field gel electrophoresis, for strain typing, 631–632, 634–636

PulseNet, 634–635, 638

PyroMark ID platform, for gastroenteritis, 539

Pyrosequencing

- for blood cultures, 659, 663

- for gastroenteritis, 538–539

Q

QuantIFERON-TB Gold Tube assay, 559

Quantitative testing, in molecular diagnosis, 718

QuickFISH, for blood cultures, 670–671, 673

Quidel assay, for respiratory viruses, 443

R

Rapid antigen test, for gastroenteritis, 529

Rapid detection

- from blood cultures, **651–684**

- history of, 706–707

RapID NF O Plus, in MALDI-TOF mass spectrometry, 621

readBruker Flex Data tool, 618

Real-time cell-analysis, for gastroenteritis, 545–546

Recognition capability, in MALDI-TOF mass spectrometry, 620

RenDx Fungiplex panel, 516–517

Resistance, antimicrobial. *See* Antimicrobial resistance.

Respiratory syncytial virus, molecular diagnosis of, 441–443, 445–448

Respiratory viruses, **439–460**

- molecular diagnosis of, 719–720

- NAATS for, 441–455

Results, communication of, 722–723

Rhinoviruses, molecular diagnosis of, 442, 448, 452, 454

Rhodotorula, MALDI-TOF mass spectrometry for, 575

Ribospacer PCR, for strain typing, 632, 636–637

RNA FISH, for fungi, 519

Rotaviruses, 528, 534–536

Round worms, 487–488

rRNA genes, in pyrosequencing, 659

S

Saccharomyces, MALDI-TOF mass spectrometry for, 575

Salivary immunoglobulin, in gastroenteritis, 544

Salmonella, 528, 535–536, 544

- strain typing of, 603, 635, 638, 643

Salmonella enterica, 534

Sapovirus, 534–535

Scedosporium, 513, 519

- Schistosomiasis, 473
- Seeplex Diarrhea ACE Detection, 535
- Seeplex Diarrhea Virus Panel, 535
- SELDI-TOF, for African trypanosomiasis, 467
- Selective reporting, 723
- Sepsis, **413–437**
 - agents causing, 652
 - biomarkers for, 415–422
 - clinical continuum of, 414–415
 - incidence of, 414
 - molecular diagnosis of, 422–429
- SepsiTest
 - for blood cultures, 662–663
 - for sepsis, 424, 428
- Sepsityper kit, 601, 613–614, 671
- SeptiFast
 - for blood cultures, 660–661, 663
 - for fungal infections, 512, 515–516
 - for sepsis, 424, 427–428
- Sequencing, **685–704**
 - clinical microbiology use of, 686–687
 - computer limitations in, 693–694
 - data interpretation in, 692–693
 - data storage problems with, 691
 - database quality and, 692
 - diversity findings in, 690
 - errors in, 692
 - evolution of, 686
 - for antimicrobial susceptibility, 695
 - for strain typing, 638
 - incidental findings in, 694–695
 - integrating into clinical diagnostics, 691
 - medical education for, 696
 - metagenomics and, 689–690
 - microbiome and, 695–696
 - open nature of, 690
 - privacy issues in, 694
 - standards for, 691–692
 - unexpected byproducts of, 687–689
- Sequencing by Oligonucleotide Ligation and Detection (SOLiD), for gastroenteritis, 539
- Serology
 - for Chagas disease, 477
 - for intestinal helminths, 487
 - for leishmaniasis, 481
 - for toxoplasmosis, 482–484
- Shear horizontal surface acoustic wave device, for gastroenteritis, 542
- Shigella*, 534–536
 - misidentification of, 612
 - strain typing of, 635
- Shock, septic. *See* Sepsis.
- Simplexa assays, for respiratory viruses, 445–446

- Simplexa *C difficile* Universal Direct Test, 530–533
- Single number polymorphisms, in strain typing, 641–642
- Single-molecule real-time sequencing, for gastroenteritis, 540
- Smart Leish re-time PCR assay, 482
- Solexa sequencing platform, for gastroenteritis, 539
- SOLiD (Sequencing by Oligonucleotide Ligation and Detection), for gastroenteritis, 539
- Spa* gene, for strain typing, 632, 638–639
- Specimen(s), MALDI-TOF mass spectrometry, 601–602, 613–614
- Specimen collection, swab methods for, 569–571
- Spectra MRSA, 667
- Spectral preprocessing, in MALDI-TOF mass spectrometry, 620
- Spirometra erinacei*, 488
- Sputum, tuberculosis biomarkers in, 560–561
- Staph ID/R Blood Culture Panel, 654, 663
- Staph SR assay, for sepsis, 422–425
- StaphPlex assay, for sepsis, 423, 425
- Staphylococcus*
 - in blood cultures, 653–656, 665, 668, 674
 - strain typing of, 635
- Staphylococcus aureus*, 540
 - classification of, 621
 - in sepsis, 422, 424–425
 - MALDI-TOF mass spectrometry for, 621
 - methicillin-resistant. *See* MRSA (methicillin-resistant *Staphylococcus aureus*).
- Staphylococcus* M assay, for sepsis, 423, 425
- Stool culture, for gastroenteritis, 528–529
- Strain typing, **639–650**
 - amplified fragment length polymorphism analysis for, 631, 634–636
 - binary typing, 633, 643–645
 - bioinformatics for, 645
 - clustered, regularly interspersed short palindromic repeats for, 632
 - culture independent testing and, 645–646
 - emm* gene typing, 632, 639
 - high-resolution fragment analysis, 632, 636–638
 - importance of, 629–630
 - k-mer based approaches, 632, 642
 - MALDI-TOF mass spectrometry for, 602–603, 622
 - methods selection for, 630–631
 - multilocus sequence typing for, 632, 639–640
 - pulsed field gel electrophoresis for, 631–632, 634–636
 - spa* gene, 632, 638–639
 - superMLST, 633, 643–645
 - whole-genome sequencing for, 632, 640–642
- Streptococcal antigen testing, for blood cultures, 664, 673
- Streptococcus*
 - in blood cultures, 656
 - MALDI-TOF mass spectrometry for, 572, 716
 - misidentification of, 612
- Streptococcus pneumoniae*
 - in blood cultures, 664, 671
 - strain typing of, MALDI-TOF mass spectrometry for, 603

Strongyloides stercoralis, 487–488
SuperMLST, for strain typing, 633, 643–645
Supervised clustering, in MALDI-TOF mass spectrometry, 620–622
Support vector machine, for MALDI-TOF mass spectrometry, 619–620
Surface acoustic wave device, for gastroenteritis, 542
Surface second harmonic generation techniques, for gastroenteritis, 542–543
Swabs, for specimen collection, 569–571
Systemic inflammatory response syndrome. *See* Sepsis.

T

T2 Biosystems fungal assays, 517
Taenia, 488
Tapeworms, 487–488
TaqMan Array Card assay, for intestinal parasites, 486
Technology, in clinical practice, **705–729**. *See also specific instruments and techniques*.
Thermostable DNase test, for blood cultures, 664
Time-resolved amplified cryptate emission (TRACE) technology, for procalcitonin, 419
Total laboratory automation, 582–584
Toxoplasmosis, 470, 544
TRACE (Time-resolved amplified cryptate emission) technology, for procalcitonin, 419
Transcriptomics, for *Mycobacterium tuberculosis*, 561
Transcription-mediated amplification assay, for trichomoniasis, 473
Trematodes, 487–488
Trichomoniasis, 473, 488–489
Trichophyton, MALDI-TOF mass spectrometry for, 576
Trichuris trichiura, 486
Trypanosomiasis
 African, 467–468
 American (Chagas disease), 476–477
Tube coagulase test, for blood cultures, 673
Tuberculosis. *See Mycobacterium tuberculosis*.
Typing and subtyping. *See* Strain typing.

U

Ulcerative colitis, 543
Urine
 MALDI-TOF mass spectrometry for, direct microorganism detection in, 601–602, 617–618
 tuberculosis biomarkers in, 559

V

Vancomycin resistance and susceptibility, *Enterococcus*, 601, 603, 622, 657
Variable number tandem repeats, for strain typing, 636
Vasopressin, in sepsis, 417, 420
Verigene *C difficile* Test, 530–531, 533–534
Verigene Gram-Negative Blood Culture Nucleic Acid Test, 663
Verigene Gram-Positive Blood Culture Nucleic Acid Test, 423, 426, 656–657, 662–663
Verigene RV+, for respiratory viruses, 446–448

Vibrio, 528, 535, 542, 548, 639
Vibrio cholerae, 546
VIDAS enzyme-linked fluorescent immunoassay, for procalcitonin, 419
Viral infections
 gastrointestinal, 528, 534–535, 544
 respiratory, **439–460**
Virulence Factors Database, 644
Virus neutralization assays, for gastroenteritis, 545
VITEK 2, for blood cultures, 664–665
Vitek AutoMicrobic system, 706, 708
VITEK MS. See bioMérieux VITEX MS.
Vittaforma, 489–490
VYOO assay, for sepsis, 424, 428

W

Walk-Away Specimen Processor, 571–572, 576–577, 708
Wampole Isolator, 652
Whole-genome sequencing, 632, 640–642
Workforce shortages, 645
Worms, intestinal, 487–488
Wuchereria bancrofti, 468, 479–480

X

Xpert *C difficile* assay, 530–532
Xpert *C difficile*/Epi assay, 530–532
Xpert MRSA/SA assay, 423–425, 663
Xpert MTV/RIF test, 556–558
xTAG Fungal ASR Luminex assay, 512, 514
xTAG Gastrointestinal Pathogen Panel, 486–487, 536–537, 721–722
xTAG Respiratory Virus Panel, 449–451
xTAG RVP FAST assays, 449–451

Y

Yeast Traffic Light PNA FISH assay, 512, 514
Yersinia, 535
Yersinia enterocolitica, 528, 535